What IKDC and MOCART scores actually measure

The IKDC Subjective Knee Score captures what patients can actually do. Its 18 questions cover everyday symptoms such as pain and swelling, sports participation, and activities of daily living, all collapsed into a single figure between 0 and 100 — where 100 represents full, unimpaired function. That scale matters most when viewed against the minimum clinically important difference (MCID): a change of 16.7 points is the threshold at which a patient is likely to notice a meaningful difference in their life. Gains below that figure may show up in statistics but rarely feel significant at the clinic or on the sports pitch.

MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — is the radiologist's counterpart. Rather than asking patients how they feel, it uses MRI to score repair tissue across parameters including the degree of defect fill, surface integrity, and how well new tissue integrates with the surrounding native cartilage. The scale also runs to 100; scores above 80 are broadly regarded as indicating excellent defect fill and sound lateral integration. Neither measure is specific to any single treatment: both are validated across cartilage repair research and used as standard benchmarks. In the data presented in the next sections, ChondroFiller patients report IKDC gains comfortably above that 16.7-point threshold, and MRI-based MOCART scores consistently exceed 80 at 12 months.

IKDC improvements at 12 months

Four prospective knee studies cited in the manufacturer's Clinical Evaluation Report (CER v09, April 2025) provide the primary 12-month functional evidence. Across all four, mean IKDC improvements consistently approximate 30 points — nearly double the 16.7-point MCID introduced above, and a gain that carries real-world weight beyond statistical significance alone.

The most detailed dataset comes from the Jerosch et al. post-market clinical follow-up (PMCF) study, which records a mean improvement of 32.4 points at 12 months. To contextualise that shift: a gain of around 30 points typically moves a patient from a score range associated with significant functional limitation — restricted daily activities, difficulty on stairs, inability to participate in low-impact sport — into a range more consistent with recreational activity and confident day-to-day function. The treatment in these studies was delivered as an injectable collagen scaffold procedure, consistent with the current outpatient ultrasound-guided pathway.

Across all four investigations the pattern holds rather than being exceptional to one cohort, which lends confidence to the signal. That said, each study is manufacturer-sponsored and designed as a prospective single-arm investigation; none is a randomised controlled trial. No large independent RCT has compared ChondroFiller injectable scaffold treatment directly against a surgical comparator on IKDC endpoints. The consistency of results across separate studies is reassuring, but independent replication would provide a stronger evidential foundation, and that qualification belongs in any shared decision-making conversation.

Does the improvement last? IKDC at 36 months

A mean IKDC score of 80.1 at three years is the clearest single answer to whether the benefit holds. That figure comes from the Jerosch et al. prospective post-market clinical follow-up (PMCF) study — currently the only published dataset that tracks ChondroFiller patients to the 36-month mark. The 32.4-point gain recorded at 12 months was not only preserved but marginally extended by year three, placing the average patient well into a functional range associated with recreational activity and confident everyday movement.

That sustained trajectory is biologically consistent with how a collagen scaffold works. A native Type I collagen matrix does not produce an immediate tissue replacement; it provides a structure that the patient's own progenitor cells migrate into and progressively remodel. Continued functional gains between 12 and 36 months align with ongoing scaffold maturation rather than a temporary symptomatic effect that fades once the acute inflammatory response subsides.

The caveat belongs alongside the result: this durability claim rests on a single study. Independent replication of the 36-month IKDC finding has not yet been published, and the Jerosch investigation, like the 12-month evidence reviewed above, is manufacturer-sponsored. The trajectory is clinically encouraging; evidentially, it awaits confirmation from independent research groups before it can be regarded as fully established. Any shared decision-making conversation should reflect that distinction honestly.

What MRI shows: MOCART scores and scaffold maturation

MRI evidence adds a structural dimension to the functional gains described above. In European knee studies, MOCART scores at 12 months range from 81.6 to 84.3 — thresholds consistent with greater than 80% defect filling and sound integration of the repair tissue with the surrounding native cartilage. Scores above 80 are generally regarded as indicating high-quality structural repair.

The more clinically instructive figure is the temporal trajectory. At four weeks post-injection, mean MOCART stands at 65.3 — reflecting the scaffold's early presence in the defect, not yet remodelled. By 12 months that figure reaches 81.6, a rise of more than 16 points across the year. This progression tracks directly with how the collagen matrix functions: rather than acting as a static implant, it provides a porous biological structure that the patient's own progenitor cells migrate into and progressively remodel, supporting the body's own repair processes over months rather than weeks.

For context across the broader ChondroFiller evidence base — which includes studies in other joints alongside the knee — published MOCART values span 70 to 87. Knee outcomes consistently sit at the upper end of that range, suggesting the joint environment is well-suited to this scaffold approach.

One gap warrants plain acknowledgement: dedicated MOCART data at 36 months are not separately reported in the available evidence. The Jerosch study's sustained 36-month functional gains are clinically encouraging, but whether the structural picture continues to improve or plateau beyond year one has not yet been quantified.

How ChondroFiller outcomes compare to surgical alternatives

Functional gains of approximately 30 points on the IKDC sit within the range reported for autologous chondrocyte implantation and matrix-assisted ACI (ACI/MACI), where published series document improvements of roughly 30 to 35 points. That comparison, drawn from the CER v09 synthesis, is cross-study rather than head-to-head: no randomised controlled trial has directly assigned patients to ChondroFiller injection versus surgical repair and measured IKDC or MOCART outcomes against a concurrent control arm. Cross-study comparisons carry inherent confounds — differing patient populations, defect sizes, and follow-up protocols — and should be read with that limitation in mind.

Where the data diverge more sharply is in the safety and reoperation profile. The complication rate recorded across ChondroFiller studies is approximately 0%, with a reoperation rate of around 3–8%. ACI/MACI, by contrast, carries complication rates of up to 17% and reoperation rates of up to 37% in published literature. Microfracture shares the low complication profile but generates fibrocartilage repair tissue that frequently degrades beyond the 12–24-month mark — a trajectory that contrasts with the sustained functional gains documented at 36 months in the Jerosch series.

For many patients the procedural dimension shapes the comparison as much as the outcome numbers. As an ultrasound-guided outpatient injectable scaffold, ChondroFiller avoids theatre admission, general anaesthetic, and the rehabilitation demands that accompany open or arthroscopic surgery — practical factors that carry real weight when patients are managing work, family, or travel commitments alongside a knee problem. This does not remove the need for careful patient selection, but it is a meaningful structural difference between pathways.

What the evidence means for patients considering treatment

Translating published data into an individual treatment decision requires one further step: establishing whether the findings apply to a specific patient. ChondroFiller is indicated for focal articular cartilage defects up to 6 cm²; suitability also depends on defect location, the condition of surrounding cartilage and subchondral bone, and overall joint health. These are factors that imaging and a structured clinical assessment can characterise — and that symptoms alone cannot.

The evidence summarised across this article is consistent and yields functional gains well above the threshold for clinical significance. Its main limitation is that it derives principally from manufacturer-sponsored prospective studies; independent replication at scale remains limited, and structural data beyond the 12-month mark have not yet been separately quantified. Patients and clinicians reviewing the option should treat the findings as a strong, consistent signal rather than a settled verdict — and factor in that individual suitability varies considerably with defect size, location, and joint status.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Consultant-led assessment, with imaging review where needed, is available at clinics in Sleaford (NG34) and Grantham (NG31); appointments can be arranged at lincolnshireknee.co.uk.